Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial Yuan WuXuefeng ZhouBo Shen Research Open access 14 October 2023 Pages: 825 - 833
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation Yujie CuiJinlong LiangHongzhen Zhang Case Report 13 October 2023 Pages: 787 - 790
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States Andrea Wang-GillamWilliam SchelmanHeather Yeckes-Rodin Research Open access 05 October 2023 Pages: 851 - 860
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid Miao LiuMaoye YuanChunjiang Wang Research 29 September 2023 Pages: 802 - 807
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma Kenta YamaokaKei IrieNobuyuki Muroi Research Open access 18 September 2023 Pages: 761 - 767
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia Tatsuji MinoHiroshi UreshinoTatsuo Ichinohe Research 13 September 2023 Pages: 751 - 760
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer Z. SunC. GuD. Li Research 30 August 2023 Pages: 737 - 750
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis Jun-yi KeShu HuangMin-chao Duan Review Open access 21 August 2023 Pages: 768 - 776
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab Markus HaasAlexander LeinBernhard J. Jank Research Open access 21 August 2023 Pages: 727 - 736
Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma Zhao GaoShikai WuXuan Jin Research 17 August 2023 Pages: 719 - 726
Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma Buthainah Ghanem Research Open access 12 August 2023 Pages: 710 - 718
Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models Rachel C.T. LamConnie W.C. HuiBrigette B.Y. Ma Research 12 August 2023 Pages: 699 - 709
Cytotoxicity of poly-guanidine in medulloblastoma cell lines Gabriel Gallo-OllerTeresita Díaz de StåhlMarcela Márquez-Méndez Research Open access 09 August 2023 Pages: 688 - 698
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study Rebecca KristeleitAlexandra LearyVivek Subbiah Research Open access 09 August 2023 Pages: 677 - 687
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation Mingzhu PanYali LiuJuan Zhang Research 05 August 2023 Pages: 664 - 676
Development and characterization of fused human arginase I for cancer therapy Snehal Sainath JawalekarPriyanka Sugriv KawatheAbhay H. Pande Research 03 August 2023 Pages: 652 - 663
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper Lina LiFengquan ChenXia Xue Research 20 July 2023 Pages: 638 - 651
Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia Carlos Eduardo de Castro AlvesSerge L. BogzaGemilson Soares Pontes Research 15 July 2023 Pages: 629 - 637
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study Chenghao ZhaoHuzheng YanMingsheng Huang Research 12 July 2023 Pages: 617 - 626
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma Yuqin SongKeshu ZhouJun Zhu Research Open access 08 July 2023 Pages: 606 - 616
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates Özkan YalkinogluAndreas BeckerRainer Strotmann Research Open access 06 July 2023 Pages: 596 - 605
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells Ibtehal MohammedAli Haider AlhammerInam Sameh Arif Research 04 July 2023 Pages: 587 - 595
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study Xue WangJinxiang HuangJian Liu Research 27 June 2023 Pages: 579 - 586
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma Hanwen LuBingchang ZhangZhanxiang Wang Research 16 June 2023 Pages: 564 - 578
POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma Yongzhao LiQidong YangGuoyan Qi Research 15 June 2023 Pages: 556 - 563
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma Elizabeth I. BuchbinderAnita Giobbie-HurderPatrick A. Ott Research 29 May 2023 Pages: 551 - 555
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma Guihong LiuYachun LuMing Chen Correction 27 May 2023 Pages: 627 - 628
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells Minhong TangJohn CrownMichael J Duffy Research Open access 26 May 2023 Pages: 541 - 550
Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies Li MaJuan MaHonggang Liu Research 17 May 2023 Pages: 522 - 531
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis Takafumi YamamotoKazuyuki MizunoHiroki Kawashima Research 12 May 2023 Pages: 512 - 521
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors Yang LuoYing ChengBinghe Xu Research Open access 12 May 2023 Pages: 503 - 511
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors Gerald S FalchookJasgit SachdevMelissa Johnson Research Open access 12 May 2023 Pages: 493 - 502
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies Danny N. KhalilIsabel Prieto González-AlboGerald A. Soff Correction 11 May 2023 Pages: 539 - 539
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles Toshiyuki TamaiMamoru Narukawa Research 10 May 2023 Pages: 483 - 492
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth Arshak R. AlexanianHeidi Marie StoellingerAlfredo Quiñones-Hinojosa Brief Report 10 May 2023 Pages: 371 - 375
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial Xiaoxue ZhuYanhua DingQingyu Wang Research 04 May 2023 Pages: 473 - 482
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients Xueyun TanSufei WangYang Jin Research Open access 04 May 2023 Pages: 463 - 472
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials Xiaoli LiYuyan LiuYuanyuan Liu Research 02 May 2023 Pages: 453 - 462
Prospective role of liquid biopsy for early screening in laryngeal cancer Xiao-yang GongHai-bing ChenXi Chen Correspondence 02 May 2023 Pages: 376 - 379
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma Shiqi HuYaqin LiuWei Qiu Review 26 April 2023 Pages: 532 - 538
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase Chan ZhangXinan ZhaoBaofeng Yu Research 25 April 2023 Pages: 438 - 452
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition Elizabeth I. BuchbinderAnita Giobbie-HurderPatrick A. Ott Brief Report 25 April 2023 Pages: 365 - 370
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study Dong-Dong JiaYu XuTao Li Research Open access 24 April 2023 Pages: 431 - 437
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors Arvind DasariErika P. HamiltonAndrew Scott Paulson Research Open access 19 April 2023 Pages: 421 - 430
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients Takehiro TozukaNoriko YanagitaniMakoto Nishio Research 14 April 2023 Pages: 411 - 420
Brigatinib pharmacokinetics in patients with chronic hepatic impairment Michael J. HanleyDavid KersteinNeeraj Gupta Research Open access 13 April 2023 Pages: 402 - 410
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy Nour AbuhadraRyan SunClinton Yam Research 12 April 2023 Pages: 391 - 401
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors Anastasios StathisAnthony W. TolcherLillian L. Siu Research Open access 11 April 2023 Pages: 380 - 390
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments Shota OmoriKoji MuramatsuToshiaki Takahashi Research 10 April 2023 Pages: 356 - 364
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer Yingying YangQingmei ZhengShansong Zheng Research Open access 10 April 2023 Pages: 254 - 266